<DOC>
	<DOCNO>NCT01492998</DOCNO>
	<brief_summary>In vitro hepatitis C virus ( HCV ) replicon system , modulation biliary salt nuclear receptor FXR either agonist antagonists respectively increases decrease replication HCV ( J Hepatol , 2008 , 48 : 192-9 ) . One antagonist FXR vegetal sterol , guggulsterone , extract Commiphora mukul tree already give safely hyper cholesterolemic patient clinical trial ( JAMA 2003 , 290 : 765-72 ) . The aim trial test effect FXR antagonist guggulsterone give orally , three time day , viral load 15 HCV genotype 1 chronically infected patient .</brief_summary>
	<brief_title>Role FXR Hepatitis C Virus Replication</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Male patient infect HCV genotype 1 , antiHCV antibody , non responder least one first line therapy Viral load &gt; 1 x 105 UI/mL 6 month treat least last two month . METAVIR score &lt; F4 Alcohol intake &gt; 20 g/day Immuno suppressive therapy Obesity BMI &gt; 30 , diabetes Dyslipidemia require specific therapy Liver cirrhosis carcinoma HIV HBV coinfections Other liver disease Major organ failure Therapy cytochrome P450 metabolize drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Biliary salt</keyword>
	<keyword>Farnesoid X receptor</keyword>
	<keyword>Guggulsterone</keyword>
</DOC>